Connect with us

Technology

Implicity’s EVIDENCE-RM Study Demonstrates Marked Improvement in ICD Patient Outcomes

Published

1 year ago

on

Comprehensive analysis of real-world data shows significant clinical and medico-economic advantages of Implicity’s universal, alert-based remote monitoring platform

CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ — IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today unveiled new findings from its EVIDENCE-RM study¹. Leveraging extensive data from the French National Health Data System (SNDS), the study demonstrated clear clinical and medico-economic benefits associated with Implicity’s universal monitoring system (UMS) compared to conventional, manufacturer-specific systems, including Abbott, Biotronik, Boston Scientific, and Medtronic.

The study, recently published in Heart Rhythm, analyzed clinical outcomes and costs for over 69,000 patients with implantable cardioverter-defibrillators (ICDs) and defibrillators with cardiac resynchronization therapy (CRT-Ds). Patients remotely monitored using Implicity’s platform showed increased survival rates and a reduction in both the number and duration of all-cause and heart failure-related hospitalizations, resulting in substantial healthcare cost reductions. Key findings attributed to Implicity’s IM009² platform include:

26% reduction in mortality (HR, 0.74; 95% CI, 0.73–0.77; P=.001)4% decrease in HF hospitalizations, total corrected healthcare costs, and mean duration of hospitalization17.8% decrease in hospital-related costs, primarily driven by decreased costs in cardiovascular disease careIncremental Cost-Effectiveness Ratio (ICER) of approximately –$112 USD (-103€) per Day Alive and Out of Hospital (DAOH) based on the French Healthcare System

“Managing patients with ICDs and CRTs presents considerable challenges, since they are at high risk of hospitalization due to arrhythmias and heart failure,” said Dr. Niraj Varma, Professor of Medicine and Director, Cardiac Pacing & Tachyarrhythmia Devices at the Cleveland Clinic. “The EVIDENCE-RM study clearly demonstrates that a universal monitoring solution operating alert-based remote monitoring can significantly reduce these risks, improving patient outcomes and substantially lowering healthcare costs. This is an important advancement in our ability to proactively manage patients with ICDs and CRTs.”

“These findings mark a pivotal moment in remote cardiac care and prove Implicity’s effectiveness with unparalleled clinical results,” stated Implicity CEO Dr. Arnaud Rosier. “A 26% reduction in mortality and better use of healthcare resources highlight the impact of universal remote monitoring, driven by AI, over fragmented manufacturer-specific systems. Implicity is committed to driving innovation so that every cardiac patient receives proactive, efficient care.”

For more information about Implicity and the EVIDENCE-RM study, please visit www.implicity.com.

About Implicity
Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI³ algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 100,000 patients in over 200 medical facilities across the US and Europe. To learn more, visit www.implicity.com

Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes

References

N. Varma et al., “Impact of a universal monitoring system (‘third party’) on outcomes of ICD patients: A nationwide study,” Heart Rhythm, 2024.IM009: 2021. Manufacturer: Implicity. IM009 is a software as a medical device (SaMD) intended to be used as an adjunct of a remote monitoring platform to follow-up target population patients. IM009 is compatible with devices with remote monitoring feature such as cardiac implantable electronic devices and connected weight scales. The three main intents of IM009 are to (1) label observations generated by medical devices according to predefined categories, (2) create clinically relevant observations for worsening atrial fibrillation and/or rapid weight gain in the context of heart failure, based on data recorded by the device and (3) label Atrial Fibrillation burden observations generated by cardiac implantable electronic device (CIED) as to be hidden or relevant for health care provider based on patient’s anticoagulation status. Hence, IM009 is designed to reduce the workload burden of healthcare providers/professionals in charge of reviewing the observations received from the patients’ devices. IM009 is not intended for use in life supporting or sustaining systems or Alarm devices and as a solely means of diagnosis. It is offered to healthcare providers/professionals on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Class I, according to Medical Device Directive 93/42/EEC. See the instructions for use for more information. Covered under the conditions defined in Article L. 162-52 of the French Social Security Code.IM007: 2021. ILR ECG ANALYZER created by Implicity is intended to be used by qualified healthcare professionals for the assessment of arrhythmias in Insertable Cardiac Monitor (ICM) ECG data. ILR ECG ANALYZER supports downloading and analyzing data recorded in compatible formats from ICMs. This version of the ILR ECG ANALYZER only supports ECG data from Medtronic ICMs. ILR ECG ANALYZER is intended to be electronically interfaced with other computer systems (remote monitoring platforms) that supply the ECG data to ILR ECG ANALYZER and receive the output of ILR ECG ANALYZER (analysis) for viewing by healthcare professionals. ILR ECG ANALYZER provides ECG signal processing and analysis, to detect asystole, bradycardia, atrial tachycardia or atrial fibrillation, ventricular tachycardia, normal rhythm and artifacts. ILR ECG ANALYZER is not for use in life supporting or sustaining systems or ECG monitor and Alarm devices. ILR ECG ANALYZER interpretation results are not intended to be the sole means of diagnosis. It is offered to physicians and clinicians on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. ILR ECG ANALYZER is interfaced with the compatible remote monitoring platform from which it receives compatible ICM data file input (Medtronic LNQ11 Medtronic REVEAL XT 9529 Medtronic REVEAL DX 9528) and to which it transmits the output. Read carefully all instructions before use. Results: sensitivity: 98.64 % (509/516), false positive rate: 24.03 % (68/283). FDA cleared Class II medical device and CE marked Class I medical device (under medical device directive 93/42).
SignalHF FDA cleared Class II medical device and CE marked Class IIa (under MDR) medical device. Manufacturer: Implicity. The SignalHF System is intended for use by qualified healthcare professionals (HCP) managing patients over 18 years old who are receiving physiological monitoring for Heart Failure surveillance and implanted with a compatible Cardiac Implantable Electronic Devices (CIED) (i.e., compatible pacemakers, ICDs, and CRTs). The SignalHF System provides additive information to use in conjunction with standard clinical evaluation. The SignalHF HF Score is intended to calculate the risk of HF for a patient in the next 30 days. This System is intended for adjunctive use with other physiological vital signs and patient symptoms and information and is not intended to independently direct therapy.
See the instructions for use for more information.

Media Contact:
Sam Choinski
eMedia Junction
860-301-5058
samantha@emediajunction.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/implicitys-evidence-rm-study-demonstrates-marked-improvement-in-icd-patient-outcomes-302436176.html

SOURCE Implicity

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BC Token Hits $0.02, Setting a New All-Time High

Published

56 minutes ago

on

July 23, 2026

By

$BC has risen nearly 70% since April as BC Engine continues to expand the token‘s utility across the BC.GAME ecosystem

BELIZE CITY, Belize, July 22, 2026 /PRNewswire/ — BC Token ($BC), the ecosystem token of BC.GAME, reached $0.02 on July 23, setting a new all-time high and extending its recent upward price movement.

According to CoinGecko, $BC reached the $0.02 milestone after moving steadily into a higher price range over the past several weeks. The token previously recorded a high of around $0.01561 on July 17 before continuing its upward movement.

Compared with its price of approximately $0.01181 on April 12, $BC has increased by nearly 70%. The latest milestone is also part of a series of new price records reached by the token since the launch of BC Engine in April.

Alongside the price growth, BC.GAME has continued to expand the practical use of $BC across its platform ecosystem.

Through BC Engine, users can allocate eligible $BC to the platform’s reward system and receive BCD rewards distributed on an hourly basis. Users can also view their allocated tokens, accumulated rewards and participation data directly through the BC Engine interface.

The system is designed to connect $BC participation with activity generated by products and partners across the wider BC.GAME ecosystem.

BC Originals, Croco Gaming and sports betting technology provider BETBY have already been integrated as Engine Nodes. Contributions from participating products and partners help support the BC Engine reward pool, creating a direct connection between platform activity, user participation and token utility.

“Reaching $0.02 is an important milestone for $BC, but price is only one part of the ecosystem’s continued development,” a BC.GAME spokesperson said. “Our focus remains on expanding the token‘s practical uses and connecting it more closely with products, rewards and user participation across the platform.”

The $BC ecosystem also includes separate buyback and token-burning mechanisms.

A portion of the tokens acquired through BC.GAME’s ongoing buyback activity may be redistributed to eligible active users through features such as Instant Bonus. The buyback programme operates separately from the token-burning mechanism.

Token burning is primarily connected to the BC Engine unlocking process. When users unlock $BC less than seven days after allocating it to BC Engine, 1% of the unlocked amount is permanently burned. Users who wait at least seven days can unlock the full amount without triggering a burn.

BC.GAME plans to introduce additional products and Engine Nodes while continuing to improve the visibility of reward distributions, token burns and other related on-chain activity.

The platform will also explore further uses for $BC across original games, sports betting and digital-asset reward experiences as the ecosystem continues to develop.

More information about BC Engine and the $BC ecosystem is available at bc.game/bc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bc-token-hits-0-02–setting-a-new-all-time-high-302832793.html

SOURCE BC.GAME

Continue Reading

Technology

BinBase Enhances 2026 USA BIN Intelligence for Durbin Compliance, Debit Network Routing, and Level 2/3 Interchange Savings

Published

56 minutes ago

on

July 23, 2026

By

BinBase updates its US payment dataset with advanced Durbin Regulation flags, ATM/Debit network routing indicators, and Level 2/3 commercial card markers to help merchants significantly reduce processing fees.

MIAMI, July 22, 2026 /PRNewswire-PRWeb/ — BinBase, a leading provider of card issuing and payment analytics data, has announced major US-focused updates to its 2026 BIN Database. Designed specifically for payment facilitators (PayFacs), US acquiring banks, and enterprise e-commerce merchants, the updated dataset targets one of the largest operational costs in payment processing: transaction interchange fees.

In the competitive US payment ecosystem, a fraction of a percent in interchange savings translates to millions of dollars for merchants. BinBase provides the exact data needed for dynamic cost-optimizing routing.

Processing credit and debit cards in the United States requires navigating complex regulatory framework and network rules. A critical element is the Durbin Amendment, which caps interchange fees on debit cards issued by regulated US banks (institutions with $10 billion or more in assets). Without precise, updated BIN-level data, payment gateways frequently misidentify unregulated cards, leading to suboptimal routing and higher processing fees.

The updated BinBase dataset addresses this challenge by providing dedicated attributes for US processing optimization:

Durbin Regulation Identification: Instant Y/N status markers allowing payment gateways to dynamically detect US regulated debit cards and apply appropriate cost structures.US Debit & ATM Network Routing: Granular routing indicators for major US PIN-debit and PINless networks, including STAR, NYCE, Pulse, and Accel, empowering payment routing engines to choose the most cost-effective path.Commercial Data Eligibility (Level 2 / Level 3): Precise identification of corporate, business, and purchasing cards eligible for Level 2/3 line-item processing, helping B2B merchants lower interchange rates on corporate transactions.Personal vs. Commercial Usage Classification: Clear distinction between consumer and corporate card ranges to prevent fee misclassification at checkout.

“In the competitive US payment ecosystem, a fraction of a percent in interchange savings translates to millions of dollars annually for high-volume merchants,” said a spokesperson for Damiko Inc. “By combining Durbin status with US debit network data and extended 8-to-11-digit precision, BinBase provides payment engineers with the exact surgical data needed to build smart, cost-optimizing routing engines.”

To evaluate the US-specific data attributes and test integration compatibility, developers can inspect the schema and download the free 2026 sample dataset on GitHub.

For complete commercial licensing, custom data exports, and enterprise integration details, visit BinBase at https://binbase.com.

About Damiko Inc

Damiko Inc is a US-based fintech data provider specializing in card issuer analytics, payment routing data, and global BIN database solutions. Operating through its flagship product, BinBase.com, the company supplies high-precision transaction intelligence to help merchants and payment facilitators worldwide optimize approval rates and mitigate processing fees.

Media Contact
Fedor Lavrikoff, BinBase, 1 7866133333, sales@binbase.com, www.binbase.com

View original content:https://www.prweb.com/releases/binbase-enhances-2026-usa-bin-intelligence-for-durbin-compliance-debit-network-routing-and-level-23-interchange-savings-302829300.html

SOURCE BinBase

Continue Reading

Technology

InfiMotion Technology Makes Public Debut, Showcasing Full-Stack E‑Drive Capabilities at Wuxi Event

Published

56 minutes ago

on

July 23, 2026

By

WUXI, China, July 22, 2026 /PRNewswire/ — InfiMotion Technology (InfiMotion), a global innovator in intelligent e‑drive systems, hosted a technology showcase event in Wuxi on July 16, marking its first public appearance as an independent supplier to the global automotive industry. The event demonstrated the company’s end‑to‑end capabilities spanning global R&D, extreme validation, and micron‑precision manufacturing – solidifying its position as a rising force in the new‑energy vehicle (NEV) drivetrain sector.

“Let the world know InfiMotion” said Joe Lin, CEO of InfiMotion Technology. “We have spent years perfecting our e‑drive technology for leading global automakers, and we are now ready to stand on our own as a trusted partner for the wider market.”

Cloud-Synced Global R&D: Engineering Without Borders

InfiMotion’s R&D network spans Wuxi, Shanghai, Ningbo, Hangzhou, and Gothenburg, with over 1,000 engineers – including a Swedish team of over 100 people – collaborating in real time via the cloud. This global footprint is built around real-world extremes: high-load endurance on European autobahns, Nordic cold starts, and tropical full-load operation in Southeast Asia – scenarios that directly shape InfiMotion’s globalization DNA.

A Track Record of Industry “Firsts”

InfiMotion’s technical pedigree speaks for itself:

2021: Pioneered China’s first self-developed 400V SiC EDU for ZEEKR 001.2024: Launched the world’s first 11-in-1 domain-controlled EDU, achieving over 90% CLTC efficiency on a 400V IGBT platform.2025: Released the world’s first mass-produced magnesium-aluminum alloy dual-motor EDU and the world’s first 900V high-performance magnesium-alloy coaxial EDU – delivering 5,200 Nm peak torque at just 77 kg net weight.

The company has also pioneered Umini-pin winding, 0.2mm ultra-thin silicon steel laminations, embedded and three-level PCM technologies, and is leading the formulation of industry standards for amorphous alloy materials.

Tested to the Extreme – Certified for Global Trust

InfiMotion adheres to ASPICE Level 3 processes and ASIL-D (ISO 26262) certification. Its validation system includes temperature cycling from -60°C to 140°C, 1,500-hour salt-spray tests, and 2,500-hour comprehensive endurance runs – with over 9,000 individual test items required for one European premium brand. The company’s CNAS-accredited testing center houses the world’s first 30,000 rpm motor test bench.

Manufacturing at Micron-Level Precision

InfiMotion operates five smart manufacturing bases across China (Wuxi, Hangzhou, Ningbo, Quzhou, and Jiaxing), with motor line automation reaching 95%. SMT accuracy is held to ±25μm, measurement instruments resolve down to 0.1μm, and an AI-driven visual inspection system detects defects as small as 20μm.

From Wuxi to the World

Today, InfiMotion supplies e-drive systems across the full voltage spectrum (400V–900V) for all vehicle classes, from A0 to supercars. Its global network spans China, Europe, and Malaysia, with vertical integration from key components to complete system. In the first half of 2026, the company ranked among China’s top three suppliers for both motor and inverter shipments, with volume production already serving Geely, Volvo, and JLR.

The InfiMotion Era Has Just Begun

As the global NEV industry undergoes profound transformation, InfiMotion remains committed to full-stack in-house R&D, global collaborative synergy, and open-win partnerships – delivering proven, traceable, and mass-producible Chinese e-drive solutions to the world.

About InfiMotion Technology

InfiMotion Technology is a global leader in the R&D and manufacturing of advanced electric drive systems and components for new energy vehicles. Committed to innovation, performance, and sustainability, InfiMotion provides comprehensive solutions empowering automakers to create the next generation of efficient, powerful, and intelligent electric vehicles.

For more information, please visit: www.infimotion.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/infimotion-technology-makes-public-debut-showcasing-full-stack-edrive-capabilities-at-wuxi-event-302832804.html

SOURCE INFIMOTION

Continue Reading

Trending